GlaxoSmithKline PLC stock price

GlaxoSmithKline PLC latest news:


  • 02/08/2018 01:30:14

    Drugmaker GSK wins fresh Advair reprieve as Novartis copy delayed

    LONDON, Feb 8 (Reuters) - GlaxoSmithKline has won another reprieve for its blockbuster Advair lung drug after U.S. regulators delayed approval of a generic copy from Novartis's Sandoz division.

  • 02/08/2018 00:17:33

    BRIEF-GSK's ViiV Healthcare Says Filed Patent Infringement Litigation Against Gilead Sciences

    Glaxosmithkline Plc(GSK): * VIIV FILES PATENT INFRINGEMENT LITIGATION. * Glaxosmithkline Plc(GSK) - VIIV ‍ANNOUNCED IT FILED PATENT INFRINGEMENT LITIGATION AGAINST GILEAD SCIENCES INC. OVER BICTEGRAVIR IN UNITED STATES AND CANADA​ Source text for Eikon: Further company coverage:

  • 02/07/2018 09:38:24

    GSK cheers investors with asthma drug sales, big dividend

    Drugmaker GlaxoSmithKline sank to a fourth-quarter loss of 546 million pounds ($758 million) from a profit of 257 million pounds a year earlier, as it dealt with U.S. tax changes.

  • 12/05/2017 15:39:23

    BRIEF-ACCC Institutes Proceedings Against GSK, Novartis

    Australian Competition and Consumer Commission. * INSTITUTED PROCEEDINGS AGAINST GLAXOSMITHKLINE HEALTHCARE AUSTRALIA PTY LTD AND NOVARTIS CONSUMER HEALTH AUSTRALASIA. * PROCEEDINGS ALLEGING THEY MADE FALSE OR MISLEADING REPRESENTATIONS IN MARKETING OF VOLTAREN OSTEO GEL AND VOLTAREN EMULGEL PAIN RELIEF PRODUCTS.

  • 11/30/2017 00:49:29

    GSK starts big African study of injectable drug to prevent HIV

    ViiV Healthcare, GlaxoSmithKline Plc's HIV unit, said on Thursday it started an African study to evaluate long-acting injectable drug for the prevention of HIV infection in sexually active women. The cabotegravir study seeks to enrol 3,200 women aged 18 to 45 years from sub-Saharan African countries, ViiV Healthcare said in a statement.

  • 11/30/2017 00:41:47

    BRIEF-Glaxosmithkline says ViiV Healthcare starts Phase 3 HIV prevention study in women

    * ‍VIIV HEALTHCARE, CO OWNED BY GSK, WITH PFIZER INC. AND SHIONOGI LTD AS SHAREHOLDERS, TO START PHASE III STUDY FOR PREVENTION OF HIV INFECTION IN SEXUALLY ACTIVE WOMEN​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

  • 11/22/2017 09:07:23

    ViiV Healthcare says FDA has approved its two-drug HIV regimen, in first such instance

    ViiV Healthcare, which is majority-owned by GlaxoSmithKline and has Pfizer Inc. and Shionogi as shareholders, said on Tuesday that the Food and Drug Administration has approved its two-drug HIV regimen. The therapy, Juluca, is the first such HIV drug composed of just two drugs -- dolutegravir and rilpivirine, both of which have been previously approved -- while other HIV regimens are typically composed of at least three drugs. This advancement could make the regimen more tolerable for the patient, according to Dr. Debra Birnkrant, director of the Division of Antiviral Products in the FDA's Center for Drug Evaluation and Research. Juluca will be priced at about $31,000-a-year, comparable to GlaxoSmithKline's three-drug HIV regimen Triumeq, suggesting that Juluca won't "'break the price' in HIV," said EvercoreISI analyst Umer Raffat. Juluca is approved for individuals with HIV-1 who have been stable on a regimen for at least half a year, have no history of treatment failure and no known resistance to Juluca's individual components, ViiV said. GlaxoSmithKline shares declined 0.8% in Tuesday trade; shares have dropped nearly 10% over the last three months, compared with a 7% rise in the S&P 500 and a nearly 8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Global Brass and Copper HoldingsBRSS | Global Cash Access HoldingsGCA | Global High Income Dollar FundGHI | Global Net LeaseGNL | Global Partners LPGLP | Global Payments Inc.GPN | Global Power Equipment Group IncGLPW | Global Ship LeaseGSL | Global Ship LeaseGSL^B | Globant S.A.GLOB |